TESARO Summarizes TSR-042 Clinical Data Presented at AACR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St futures rise as US, Iran pause hostilities
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Oil prices drop after US, Iran pause fighting over weekend
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Tesoro (TSRO) Data Supportive of Future Combos - Cowen
April 16, 2018 12:45 PM EDTCowen analyst Boris Peaker reiterated a Market Perform rating and $66 price target on Tesaro (NASDAQ: TSRO) after the company reported MSI-H endometrial and NSCLC expansion cohort data for TSR-042 (anti-PD-1 mAb) at AACR.
"Response rates of 46.7% and 29.2%, respectively, appear competitive in these two... More
